Product Code: BMIRE00029110
The Asia Pacific radioactive tracer market was valued at US$ 1,615.80 million in 2022 and is expected to reach US$ 6,629.61 million by 2030; it is estimated to grow at a CAGR of 19.3% from 2022 to 2030.
Rising Prevalence of Chronic Diseases fuel the Asia Pacific Radioactive Tracer Market
Increasing aging population, changing social behavior, rising adoption of a sedentary lifestyle, and accelerating urbanization are the key factors boosting the prevalence of obesity and other chronic diseases such as diabetes. Further, studies have long established that genes can cause chronic conditions such as cardiovascular disease (CVD), diabetes, obesity, Alzheimer's disease (AD), and depression.
CVDs, such as atherosclerosis, angina pectoris, and acute myocardial infarction, caused due to hectic lifestyles have become significant causes of mortality worldwide. As per the data provided by the WHO, CVDs are the predominant cause of death worldwide, recording estimated 17.9 million deaths each year. Diabetes is a life-threatening chronic disease with no functional cure. Diabetes of all types can lead to various complications in different body parts and increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are among the major complications associated with diabetes. The disease prevalence will likely increase by nearly 35% during the forecast period.
Thus, an effective examination is a must for properly treating chronic diseases; hence, nuclear substances are used for diagnosis and examination purposes. These nuclear substances are used in diagnostic tests such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) to diagnose chronic diseases such as neurological, cardiovascular, chronic lung, and chronic kidney diseases. the availability of several radiotracer across the globe makes it selection easy depending on the type of disease and its prognosis. Thus, the increasing incidences of chronic diseases are surging the demand for radioactive tracer, positively favoring market expansion.
Asia Pacific Radioactive Tracer Market Overview
The Asia Pacific radioactive tracer market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. The market in the region is likely to continue to grow at the fastest rate during the forecast period owing to factors such as the development of new research facilities, the rise in the geriatric population and significant evolution of hybrid systems with technological advancement in the field of imaging.
Asia Pacific Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Radioactive Tracer Market Segmentation
The Asia Pacific radioactive tracer market is segmented based on tracer type, test type, end user, application, and country. Based on tracer type, the Asia Pacific radioactive tracer market is segmented into technetium-99m & Tc-97m, iodine-131, iron-59, lutetium-171, rubidium (Rb-82) chloride & ammonia (N-13), scandium-46, seaborgium-269, hassium-269, Gallium citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), phosphorus-32 & chromium-51, thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and others. The others segment held the largest market share in 2022.
Based on test type, the Asia Pacific radioactive tracer market is segmented into PET, SPECT, and others. The SPECT segment held the largest market share in 2022.
Based on end user, the Asia Pacific radioactive tracer market is segmented into hospitals & clinics, diagnostic centers, academic & research institutes, and others. The hospitals & clinics segment held the largest market share in 2022.
Based on application, the Asia Pacific radioactive tracer market is segmented into oncology, pulmonary, neurology, cardiology, and others. The oncology segment held the largest market share in 2022.
Based on country, the Asia Pacific radioactive tracer market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific radioactive tracer market share in 2022.
Rotem Industries Ltd, Invicro LLC, Cardinal Health Inc, Newcastle University, Novartis AG, Curium, and IBA Radiopharma Solutions are some of the leading players operating in the Asia Pacific radioactive tracer market.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific radioactive tracer market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific radioactive tracer market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific radioactive tracer market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Asia Pacific Radioactive Tracer Market - Key Industry Dynamics
- 4.1 Key Market Drivers:
- 4.1.1 Rising Prevalence of Chronic Diseases
- 4.1.2 Increasing Use of Nuclear Imaging Techniques
- 4.2 Market Restraints
- 4.2.1 Short Shelf-Life of Radioactive Tracer
- 4.2.2 Availability of Substitutes to Nuclear Diagnostic Imaging Procedures
- 4.3 Market Opportunities
- 4.3.1 Presence of Emerging Economies and Growing Population
- 4.3.2 Development of Personalized Radiopharmaceuticals for Targeted Therapies
- 4.4 Future Trends
- 4.4.1 Use of Radioactive Tracer in Cancer Diagnosis
- 4.5 Impact Analysis:
5. Radioactive Tracer Market - Asia Pacific Market Analysis
- 5.1 Radioactive Tracer Market Revenue (US$ Mn), 2022 - 2030
6. Asia Pacific Radioactive Tracer Market - Revenue and Forecast to 2030 - by Tracer Types
- 6.1 Overview
- 6.2 Radioactive Tracer Market Revenue Share, by Tracer Types 2022 & 2030 (%)
- 6.3 Technetium 99m and TC-97m
- 6.3.1 Overview
- 6.3.2 Technetium 99m and TC-97m: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4 Iodine 131
- 6.4.1 Overview
- 6.4.2 Iodine 131: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.5 Iron 59
- 6.5.1 Overview
- 6.5.2 Iron 59: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.6 Lutetium- 171
- 6.6.1 Overview
- 6.6.2 Lutetium- 171: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.7 RB82 and ammonia N-13
- 6.7.1 Overview
- 6.7.2 RB82 and ammonia N-13: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.8 Scandium 46
- 6.8.1 Overview
- 6.8.2 Scandium 46: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.9 Seaborgium-269
- 6.9.1 Overview
- 6.9.2 Seaborgium-269: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.10 Hassium -269
- 6.10.1 Overview
- 6.10.2 Hassium -269: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.11 Gallium Citrate GA 67
- 6.11.1 Overview
- 6.11.2 Gallium Citrate GA 67: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.12 PSMA GA68
- 6.12.1 Overview
- 6.12.2 PSMA GA68: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.13 FDDNP (F-18) and FDOPA (f-18)
- 6.13.1 Overview
- 6.13.2 FDDNP (F-18) and FDOPA (f-18): Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.14 Phosphorus 32 and Chromium -51
- 6.14.1 Overview
- 6.14.2 Phosphorus 32 and Chromium -51: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.15 Thallium-201
- 6.15.1 Overview
- 6.15.2 Thallium-201: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.16 F-18 FDG
- 6.16.1 Overview
- 6.16.2 F-18 FDG: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.17 F-18 FAPI
- 6.17.1 Overview
- 6.17.2 F-18 FAPI: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.18 GA 68 FAPI
- 6.18.1 Overview
- 6.18.2 GA 68 FAPI: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.19 F-18 PSMA
- 6.19.1 Overview
- 6.19.2 F-18 PSMA: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.20 DOTATOC/DOTANOC/DOTATATE Ga 68
- 6.20.1 Overview
- 6.20.2 DOTATOC/DOTANOC/DOTATATE Ga 68: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 6.21 Others
- 6.21.1 Overview
- 6.21.2 Others: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Radioactive Tracer Market - Revenue and Forecast to 2030 - by Test Type
- 7.1 Overview
- 7.2 Radioactive Tracer Market Revenue Share, by Test Type 2022 & 2030 (%)
- 7.3 PET
- 7.3.1 Overview
- 7.3.2 PET: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 SPECT
- 7.4.1 Overview
- 7.4.2 SPECT: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Radioactive Tracer Market - Revenue and Forecast to 2030 - by Application.
- 8.1 Overview
- 8.2 Radioactive Tracer Market Revenue Share, by Application 2022 & 2030 (%)
- 8.3 Oncology
- 8.3.1 Overview
- 8.3.2 Oncology: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 8.4 Pulmonary
- 8.4.1 Overview
- 8.4.2 Pulmonary: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 8.5 Neurology
- 8.5.1 Overview
- 8.5.2 Neurology: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 8.6 Cardiology
- 8.6.1 Overview
- 8.6.2 Cardiology: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Radioactive Tracer Market - Revenue and Forecast to 2030 - by End User
- 9.1 Overview
- 9.2 Radioactive Tracer Market Revenue Share, by End User 2022 & 2030 (%)
- 9.3 Hospitals and Clinics
- 9.3.1 Overview
- 9.3.2 Hospitals and Clinics: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4 Diagnostic Centers
- 9.4.1 Overview
- 9.4.2 Diagnostic Centers: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5 Academic and Research Institutes
- 9.5.1 Overview
- 9.5.2 Academic and Research Institutes: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
- 9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Radioactive Tracer Market - Country Analysis
- 10.1 Asia Pacific Radioactive Tracer Market, Revenue and Forecast to 2030
- 10.1.1 Overview
- 10.1.2 Asia Pacific Radioactive Tracer Market by Country
- 10.1.2.1 China
- 10.1.2.1.1 Overview
- 10.1.2.1.2 China Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.2.1.3 China Radioactive Tracer Market, by Tracer Types
- 10.1.2.1.4 China Radioactive Tracer Market, by Test Type
- 10.1.2.1.5 China Radioactive Tracer Market, by Application
- 10.1.2.1.6 China Radioactive Tracer Market, by End-User
- 10.1.2.2 Japan
- 10.1.2.2.1 Overview
- 10.1.2.2.2 Japan Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.2.2.3 Japan Radioactive Tracer Market, by Tracer Types
- 10.1.2.2.4 Japan Radioactive Tracer Market, by Test Type
- 10.1.2.2.5 Japan Radioactive Tracer Market, by Application
- 10.1.2.2.6 Japan Radioactive Tracer Market, by End-User
- 10.1.2.3 India
- 10.1.2.3.1 Overview
- 10.1.2.3.2 India Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.2.3.3 India Radioactive Tracer Market, by Tracer Types
- 10.1.2.3.4 India Radioactive Tracer Market, by Test Type
- 10.1.2.3.5 India Radioactive Tracer Market, by Application
- 10.1.2.3.6 India Radioactive Tracer Market, by End-User
- 10.1.2.4 Australia
- 10.1.2.4.1 Overview
- 10.1.2.4.2 Australia Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.2.4.3 Australia Radioactive Tracer Market, by Tracer Types
- 10.1.2.4.4 Australia Radioactive Tracer Market, by Test Type
- 10.1.2.4.5 Australia Radioactive Tracer Market, by Application
- 10.1.2.4.6 Australia Radioactive Tracer Market, by End-User
- 10.1.2.5 South Korea
- 10.1.2.5.1 Overview
- 10.1.2.5.2 South Korea Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.2.5.3 South Korea Radioactive Tracer Market, by Tracer Type
- 10.1.2.5.4 South Korea Radioactive Tracer Market, by Test Type
- 10.1.2.5.5 South Korea Radioactive Tracer Market, by Application
- 10.1.2.5.6 South Korea Radioactive Tracer Market, by End-User
- 10.1.2.6 Rest of Asia Pacific
- 10.1.2.6.1 Overview
- 10.1.2.6.2 Rest of Asia Pacific Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.2.6.3 Rest of Asia Pacific Radioactive Tracer Market, by Tracer Types
- 10.1.2.6.4 Rest of Asia Pacific Radioactive Tracer Market, by Test Type
- 10.1.2.6.5 Rest of Asia Pacific Radioactive Tracer Market, by Application
- 10.1.2.6.6 Rest of Asia Pacific Radioactive Tracer Market, by End-User
11. Radioactive Tracer Market Industry Landscape
- 11.1 Overview
- 11.2 Organic Developments
- 11.3 Inorganic Developments
12. Radioactive Tracer Market, Key Company Profiles
- 12.1 Rotem Industries Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Invicro LLC
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Cardinal Health Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Newcastle University
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Novartis AG
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Curium
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 General Electric Co
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 IBA Radiopharma Solutions
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
13. Appendix
- 13.1 About Us
- 13.2 Glossary of Terms